Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following yesterday’s topline data from the Batoclimab Myasthtenia ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

INTERVIEW WITH SALVATORE ROSSI, former Director General of the Bank of Italy. "Cryptocurrencies are the chips of a gigantic gambling game" and, if Trump's project of deregulation and creation of ...

Indriatti Van Hien will succeed the ‘well-known and well-regarded UK small-cap manager’ in running the Henderson Smaller ...